{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:12:42Z","timestamp":1793128362981,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is one of the most aggressive types of breast cancer (BC), most commonly diagnosed in young premenopausal women. It is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). For this reason, therapeutic options using hormone therapy or targeted anti-HER2 treatment are significantly limited. TNBC is associated with a poor prognosis, which requires the search for new treatment strategies. A promising option is the use of an antibody-drug conjugate (ADC) directed against Trophoblast cell-surface antigen 2 (Trop-2), namely Sacituzumab govitecan (SG). Recent findings indicate that, beyond its direct cytotoxic effect, SG may also induce immunogenic cell death, remodel the tumor immune microenvironment, and enhance antitumor immune responses\u2014features that make it a molecule of particular relevance in immuno-oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A systematic review was conducted based on databases from PubMed, Web of Science and the ClinicalTrials.gov registry using the keywords: \u2018Sacituzumab govitecan\u2019, \u2018Triple-negative breast cancer\u2019, \u2018Antibody\u2013drug conjugate\u2019, \u2018metastatic triple-negative breast cancer\u2019, \u2018Trop-2\u2019. The inclusion criteria covered studies from 2017 to 2025. Ultimately, after a thorough analysis, 4 randomized controlled trials (RCTs) and 4 single-arm studies were included in the review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of clinical trial results evaluating the safety and efficacy of SG in TNBC therapy showed promising therapeutic potential for the drug. Significant improvements were observed in key clinical parameters, such as overall response rate (ORR) and progression-free survival (PFS). In addition, the safety profile was acceptable and consistent with previous reports, with the most commonly reported adverse events being neutropenia, diarrhea and alopecia, which were well controlled in most cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to its aggressive course and poor prognosis, TNBC remains a therapeutic challenge. SG is a promising therapeutic option, but further studies are needed, especially randomized controlled trials and studies on combinations with immunotherapy, to improve treatment outcomes and quality of life for patients. Importantly, SG also exhibits immunomodulatory potential through the induction of immunogenic cell death and enhancement of immune effector activity, positioning it as a bridge between cytotoxic and immune-based therapeutic strategies in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1679648","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:13:09Z","timestamp":1768205589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Julia","family":"Piekarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Picheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Pobide\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szklener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sk\u00f3rzewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S516542","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: A review","volume":"17","author":"Jie","year":"2025","journal-title":"Breast Cancer Targets Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194571","article-title":"BRCA mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making","volume":"14","author":"Pavese","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12672-025-02227-6","article-title":"A comprehensive review on targeted therapies for triple-negative breast cancer: an evidence-based treatment guideline","volume":"16","author":"Emara","year":"2025","journal-title":"Discov Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.01.008","article-title":"Antibody\u2013drug conjugates in triple negative breast cancer","volume":"24","author":"Keskinkilic","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041242","article-title":"Advances in targeted therapy of breast cancer with antibody-drug conjugates","volume":"15","author":"Subhan","year":"2023","journal-title":"Pharmaceutics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.11995006","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan","volume":"31","author":"Tolaney","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by HER2 and TROP2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1513421","article-title":"Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review","volume":"15","author":"Serrano Garc\u00eda","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080876","article-title":"TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy","volume":"9","author":"Singh","year":"2021","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple-negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)","volume":"31","author":"P aluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1302645","article-title":"Genetic contribution of breast cancer genes in women of black African origin","volume":"14","author":"Ndiaye","year":"2023","journal-title":"Front Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101791","article-title":"Overall survival and prognostic factors in metastatic triple-negative breast cancer: a National Cancer Database analysis","volume":"16","author":"Kesireddy","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic TNBC: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.4274\/ejbh.galenos.2020.5909","article-title":"The relationship of mutation carriage of BRCA1\/2 and family history in triple-negative breast cancer: experience from a diagnostic center in Turkey","volume":"17","author":"Duzkale","year":"2021","journal-title":"Eur J Breast Health"},{"key":"B22","first-page":"101","article-title":"Prognostic significance and molecular classification of triple negative breast cancer: a systematic review","volume":"21","author":"Dogra","year":"2025","journal-title":"Eur J Breast Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2022","journal-title":"Front Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12748","article-title":"Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies","volume":"14","author":"Khosravi-Shahi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"biomark Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Mol Basel Switz"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02589-x","article-title":"Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","volume":"29","author":"Naito","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B35","volume-title":"FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer","year":"2025"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"B37","unstructured":"FDA label"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"OncoImmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02589-x","article-title":"Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","volume":"29","author":"Naito","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer: results from BrighTNess","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis in triple-negative breast cancers: a pooled individual patient analysis","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-Trop-2 antibody-drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34424","article-title":"A Phase IIb, single-arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06602-7","article-title":"Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"195","author":"O\u2019Shaughnessy","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106","article-title":"SACI-IO TNBC: randomized phase II trial of sacituzumab govitecan \u00b1 pembrolizumab in PD-L1- metastatic triple-negative breast cancer","volume":"39","author":"Garrido-Castro","year":"2021","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in previously untreated PD-L1-positive advanced TNBC: primary results from ASCENT-04\/KEYNOTE-D19","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213622","article-title":"Sacituzumab govitecan in triple negative breast cancer: a systematic review of clinical trials","volume":"16","author":"P\u00e9rez-Bermejo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial","volume":"29","author":"Ring","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1186\/s12885-024-12953-9","article-title":"Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study","volume":"24","author":"Ni","year":"2024","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/10600280231164110","article-title":"Sacituzumab govitecan as a second-line treatment in relapsed\/refractory metastatic triple-negative breast cancer patients: a systematic review and meta-analysis","volume":"58","author":"Kathpalia","year":"2024","journal-title":"Ann Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105308","article-title":"Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States","volume":"10","author":"Nanda","year":"2025","journal-title":"ESMO Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70213","article-title":"Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: a multicenter study by the Turkish Oncology Group","author":"Tunbekici","year":"2025","journal-title":"Int J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251316433","article-title":"Targeted therapy in TNBC: exploring the role of antibody-drug conjugates with a focus on sacituzumab govitecan","volume":"31","author":"Siddiqui","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2267975","article-title":"Managing adverse events of sacituzumab govitecan","volume":"23","author":"Schlam","year":"2023","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:13:11Z","timestamp":1768205591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2025.1679648"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1679648","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1679648"}}